Pharmaceutical The recent approval of Hua Medicine’s first-in-class diabetes drug - HuaTangNing (dorzagliatin tablets, HMS5552) - in China, in collaboration with Germany’s Bayer, puts an end to a decade-long wait for molecules with a new mechanism of action, as well as marked the initiation of international partnerships by domestic companies for T2D market in China, says data and analytics company GlobalData. 29 November 2022